Clinical Trials Unit
Stanford University School of Medicine's Center for Advanced Dermatologic Investigation is the Dermatology Department's clinical trials unit.
The Center is home to 12-15 ongoing clinical studies, investigating the safety and efficacy of new and currently available drugs and over-the-counter medications. The Center works with Stanford's own panel on medical research, leading pharmaceutical companies,and the Food and Drug Administration to safely and ethically expand the medical field's knowledge of dermatologic treatments. New studies begin regularly, and the Center continues to recruit patients with skin aging, sun damage, skin cancer (including basal cell carcinomas), psoriasis, atopic dermatitis, rosacea, and other dermatologic diseases for ongoing studies.
Skin Aging Studies
We seek to understand the human aging processes as it relates to skin on a fundamental level. To this end, our studies focus on clinical and translational research efforts ranging from: (1) the analysis of gene changes which predispose individuals to exceptionally youthful skin to (2) molecular signatures that may be biomarkers for aging skin to (3) the careful study of new candidate agents which might affect the skin aging process.
Nonmelanoma Skin Cancer
Recent advances in our understanding of basal cell skin cancer biology have enabled the development of cutting edge study drugs which combat tumor growth. We are currently home to a number of clinical trials at the forefront of potential therapy for advanced or metastatic basal cell cancer. In addition, we seek to understand the biology of basal cell skin cancers and to identify molecular predictors for treatment success.
Acne Rosecea
This is a common and frustrating chronic inflammatory condition of the face, usually affecting older individuals. The causes of this complex condition are the subject of much study. Our clinical studies seek to identify new topical or oral medications to improve the symptoms of acne rosacea.
Contact
For more information, please email dermtrials@stanford.edu
Featured Clinical Trials
Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease
This is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, including tolerability, of ISIS 681257 and to assess the efficacy of different doses and dosing regimens of ISIS 681257 for reduction of plasma Lipoprotein(a) [Lp(a)] levels in participants with hyperlipoproteinemia(a) and established cardiovascular disease (CVD).
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: ISIS 681257
- drug: Placebo
Eligibility
Key Inclusion Criteria:
- Clinical diagnosis of CVD defined as documented coronary artery disease, stroke, or
peripheral artery disease
- Lp(a) plasma level ≥ 60 mg/dL
- Must be on standard-of-care preventative therapy for other than elevated Lp(a) CVD
risk factors
Key Exclusion Criteria:
- Within 6 months of Screening: acute coronary syndrome, major cardiac surgery, or
stroke/TIA
- Within 3 months of Screening: coronary, carotid, or peripheral arterial
revascularization, major non-cardiac surgery, or lipoprotein apheresis
- Heart failure New York Heart Association (NYHA) class IV
Ages Eligible for Study
18 Years - 80 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Psoriasis Clinical Trials
Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease
This is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, including tolerability, of ISIS 681257 and to assess the efficacy of different doses and dosing regimens of ISIS 681257 for reduction of plasma Lipoprotein(a) [Lp(a)] levels in participants with hyperlipoproteinemia(a) and established cardiovascular disease (CVD).
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: ISIS 681257
- drug: Placebo
Eligibility
Key Inclusion Criteria:
- Clinical diagnosis of CVD defined as documented coronary artery disease, stroke, or
peripheral artery disease
- Lp(a) plasma level ≥ 60 mg/dL
- Must be on standard-of-care preventative therapy for other than elevated Lp(a) CVD
risk factors
Key Exclusion Criteria:
- Within 6 months of Screening: acute coronary syndrome, major cardiac surgery, or
stroke/TIA
- Within 3 months of Screening: coronary, carotid, or peripheral arterial
revascularization, major non-cardiac surgery, or lipoprotein apheresis
- Heart failure New York Heart Association (NYHA) class IV
Ages Eligible for Study
18 Years - 80 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Dermatology Clinical Trials
Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease
This is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, including tolerability, of ISIS 681257 and to assess the efficacy of different doses and dosing regimens of ISIS 681257 for reduction of plasma Lipoprotein(a) [Lp(a)] levels in participants with hyperlipoproteinemia(a) and established cardiovascular disease (CVD).
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: ISIS 681257
- drug: Placebo
Eligibility
Key Inclusion Criteria:
- Clinical diagnosis of CVD defined as documented coronary artery disease, stroke, or
peripheral artery disease
- Lp(a) plasma level ≥ 60 mg/dL
- Must be on standard-of-care preventative therapy for other than elevated Lp(a) CVD
risk factors
Key Exclusion Criteria:
- Within 6 months of Screening: acute coronary syndrome, major cardiac surgery, or
stroke/TIA
- Within 3 months of Screening: coronary, carotid, or peripheral arterial
revascularization, major non-cardiac surgery, or lipoprotein apheresis
- Heart failure New York Heart Association (NYHA) class IV
Ages Eligible for Study
18 Years - 80 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Pediatric Dermatology Clinical Trials
Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease
This is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, including tolerability, of ISIS 681257 and to assess the efficacy of different doses and dosing regimens of ISIS 681257 for reduction of plasma Lipoprotein(a) [Lp(a)] levels in participants with hyperlipoproteinemia(a) and established cardiovascular disease (CVD).
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: ISIS 681257
- drug: Placebo
Eligibility
Key Inclusion Criteria:
- Clinical diagnosis of CVD defined as documented coronary artery disease, stroke, or
peripheral artery disease
- Lp(a) plasma level ≥ 60 mg/dL
- Must be on standard-of-care preventative therapy for other than elevated Lp(a) CVD
risk factors
Key Exclusion Criteria:
- Within 6 months of Screening: acute coronary syndrome, major cardiac surgery, or
stroke/TIA
- Within 3 months of Screening: coronary, carotid, or peripheral arterial
revascularization, major non-cardiac surgery, or lipoprotein apheresis
- Heart failure New York Heart Association (NYHA) class IV
Ages Eligible for Study
18 Years - 80 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease
This is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, including tolerability, of ISIS 681257 and to assess the efficacy of different doses and dosing regimens of ISIS 681257 for reduction of plasma Lipoprotein(a) [Lp(a)] levels in participants with hyperlipoproteinemia(a) and established cardiovascular disease (CVD).
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: ISIS 681257
- drug: Placebo
Eligibility
Key Inclusion Criteria:
- Clinical diagnosis of CVD defined as documented coronary artery disease, stroke, or
peripheral artery disease
- Lp(a) plasma level ≥ 60 mg/dL
- Must be on standard-of-care preventative therapy for other than elevated Lp(a) CVD
risk factors
Key Exclusion Criteria:
- Within 6 months of Screening: acute coronary syndrome, major cardiac surgery, or
stroke/TIA
- Within 3 months of Screening: coronary, carotid, or peripheral arterial
revascularization, major non-cardiac surgery, or lipoprotein apheresis
- Heart failure New York Heart Association (NYHA) class IV
Ages Eligible for Study
18 Years - 80 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting
Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease
This is a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the safety, including tolerability, of ISIS 681257 and to assess the efficacy of different doses and dosing regimens of ISIS 681257 for reduction of plasma Lipoprotein(a) [Lp(a)] levels in participants with hyperlipoproteinemia(a) and established cardiovascular disease (CVD).
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: ISIS 681257
- drug: Placebo
Eligibility
Key Inclusion Criteria:
- Clinical diagnosis of CVD defined as documented coronary artery disease, stroke, or
peripheral artery disease
- Lp(a) plasma level ≥ 60 mg/dL
- Must be on standard-of-care preventative therapy for other than elevated Lp(a) CVD
risk factors
Key Exclusion Criteria:
- Within 6 months of Screening: acute coronary syndrome, major cardiac surgery, or
stroke/TIA
- Within 3 months of Screening: coronary, carotid, or peripheral arterial
revascularization, major non-cardiac surgery, or lipoprotein apheresis
- Heart failure New York Heart Association (NYHA) class IV
Ages Eligible for Study
18 Years - 80 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Recruiting